Τίτλος:
Gene therapy in systemic lupus erythematosus
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Despite the fact that the etiopathogenesis of systemic lupus erythematosus is largely unknown, key steps in the pathophysiology of the disease have been recognized and targeted using gene therapy techniques. In animal models of lupus, gene transfer has been used to block the action of pro-inflammatory cytokines and co-stimulatory molecules leading to clinical improvement. In humans, ex vivo experiments have shown the feasibility of gene transfer in live T cells and its potential for restoring normal phenotype in T cells from patients with lupus. Still in experimental phase, gene therapy in lupus promises to correct the aberrant immunological response without the numerous side-effects of the currently used immunosuppressant medications. © 2005 Bentham Science Publishers Ltd.
Συγγραφείς:
Kyttaris, V.C.
Sfikakis, P.P.
Juang, Y.-T.
Tsokos, G.C.
Περιοδικό:
Current Gene Therapy
Λέξεις-κλειδιά:
adenovirus vector; antisense oligonucleotide; cytotoxic T lymphocyte antigen 4; FAS ligand; gamma interferon; gamma interferon receptor; gonadorelin; immunoglobulin A; immunosuppressive agent; interleukin 2; interleukin 4 antibody; monocyte chemotactic protein 1; protein kinase (calcium,calmodulin); T lymphocyte receptor gamma chain; transforming growth factor beta, antigen presenting cell; cytokine production; cytomegalovirus infection; ex vivo study; feasibility study; gene targeting; gene transfer; genetic predisposition; human; immune response; in vitro study; nonhuman; nonviral gene delivery system; nonviral gene therapy; phenotype; plasmid; review; sialoadenitis; side effect; survival rate; systemic lupus erythematosus; T lymphocyte; treatment outcome; viral gene delivery system; viral gene therapy, Animals; Chemokines; Gene Therapy; Genetic Engineering; Genetic Predisposition to Disease; Humans; Lupus Erythematosus, Systemic; Models, Animal; T-Lymphocytes, Adenoviridae; Animalia; Cytomegalovirus
DOI:
10.2174/156652305774964703
